Search

Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform

Striving to revolutionize mental health research

World Mental Health Day: We are committed to transforming the mental health landscape through precision psychiatry

Across Cancer Types

Prioritizing mental health and well-being today and every day

Prioritizing Mental Health and Well-being Today and Everyday

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Why today’s depression trials demand smart new approaches

Big Little Things: In cancer, small things make a big impact

Little things can be a big deal when you are living with or treating cancer. “Big Little Things” celebrates the small things that have a big impact.

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Gastrointestinal Cancers

Lung Cancer

A Brave New World: Digital Health Redo | Boehringer Ingelheim US

Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Investigating MDM2-p53 in cancer

Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.

Expert insights: top online lung cancer questions answered

As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.

Sustainable cattle production: Feeding the world while minimizing environmental effect

Real-world data announced for adults with type 2 diabetes

Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult

Sites Around the World

Click here to view our biggest sites. With 52,000 employees worldwide, Boehringer Ingelheim has a research and production network across the globe.

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

Larry's Story: The Power of Patient Advocacy

For Larry, patient advocacy is an important part of his cancer journey. Learn more about Larry and his role with GO2 for Lung Cancer.

Overcoming stigma and advancing lung cancer advocacy

As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.

Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World

Partnering Days

Positive results reported in HER2 mutated lung cancer

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

Cooking Up Change: Boehringer Cares Foundation and World Central Kitchen’s Recipe for Fighting Hunger

Our Boehringer Cares team has partnered with World Central Kitchen who aim to address the critical issue of global food insecurity.

Oncology & Cancer Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers